viewVerona Pharma

Verona Pharma starts Asthma drug trial


Verona Pharma (LON:VRP) has begun a new clinical trial to evaluate higher dosing of its key asthma drug, RPL554.

The trial will help Verona set the dosage for a subsequent trial, which will test the drug's effectiveness over a period of days. 

The second trial will also assess the anti-inflammatory effect of the drug.

"We are delighted that this trial to further clarify the therapeutic usefulness of RPL554 is underway,” chief executive Professor Michael Walker said.

“We believe that, combined with the second trial, we will demonstrate the safety of RPL554 at higher doses as well as its significant potential as a bronchodilator and anti-inflammatory drug,

“The trials are expected to add value and satisfy questions raised by potential development partners in the company's licensing discussions which are ongoing."

The first patient in the trial has now been treated at the Centre for Human Drug Research (CHDR) in Leiden, The Netherlands.

The asthma drug is designed to inhibit two enzymes that are known to effect the development and progression of inflammatory respiratory diseases.

Verona highlighted that a previous Phase I/IIa trial demonstrated safety and effective bronchodilation, using lower doses.


Quick facts: Verona Pharma

Price: 46.5 GBX

Market: AIM
Market Cap: £49.54 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Verona Pharma named herein, including the promotion by the Company of Verona Pharma in any Content on the Site, the Company receives from said...


2 min read